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Abstract The snake venom protease ecarin from Echis
carinatus was expressed in stable transfected CHO-S cells
grown in animal component free cell culture medium.
Recombinant ecarin (r-ecarin) was secreted from the sus-
pension adapted Chinese Hamster Ovary (CHO-S) host
cells as a pro-protein and activation to the mature form of
r-ecarin occurred spontaneously during continued incuba-
tion of the cell culture at 37 C after death of the host cells.
Maximal ecarin activity was reached 7 days or more after
cell culture viability had dropped to zero. The best pro-
ducing CHO-S clone obtained produced up to 7,000 EU
ecarin/litre in lab scale shaker cultures. The conversion
of different concentrations of both prothrombin and
prethrombin-2 as substrates for native and r-ecarin were
examined with a chromogenic thrombin substrate. At low
concentrations both these proteins were converted into
thrombin by the two ecarin preparations with comparable
rates. However, with prothrombin concentrations above
250 nM r-ecarin apparently had a two times higher turn-
over than native ecarin, consistent with the observed rapid
complete conversion of prothrombin into thrombin by
r-ecarin. With r-ecarin a Km value of 0.4 lM prethrombin-2
was determined but only a rough estimate could be made of
the Km for prothrombin of 0.9 lM. In conclusion, r-ecarin
was identiﬁed as a promising candidate for replacement of
native ecarin in assays utilizing conversion of prothrombin
to thrombin.
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1 Introduction
There is a clinical need to be able to quantify both func-
tional and non-functional prothrombin in plasma. Func-
tionally active prothrombin contains a GLA-domain
containing ten glutamic acid residues that are post-trans-
lationally converted into c-carboxyglutamate (Glx). Inac-
tive prothrombin that lacks Glx residues is in vivo present
under conditions of cancer [2, 3, 11] or by the use of
warfarin [10]. In vivo, thrombin is generated only from
functionally active prothrombin in series of cleavage steps
by coagulation factor Xa (FXa) cleavage in a GLA-domain
and Ca
2?-dependent process, giving rise to different
intermediates as prethrombin-2 or meizothrombin.
Ecarin is a component of the venom from the saw-scaled
viper Echis carinatus that can convert prethrombin-2 to
thrombin [12] or prothrombin to meizothrombin, which
subsequentlywillbeconvertedtothrombinbyauto-catalytic
activity [8]. In contrast to FXa-like snake venom pro-
thrombin activators, the ecarin protease activity does not
depend on additional co-factors or calcium ions neither on
thepresenceofaGLAdomain[9].Therefore,ecarinpuriﬁed
from snake venom is currently used in vitro as prothrombin
activator in diagnostic reagents for measurement of total
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determination of direct thrombin inhibitors [5].
The cloning of the ecarin mRNA sequence was pub-
lished more than 15 years ago [6] and recombinant GLA-
domain–less prethrombin-2 digested with recombinant
ecarin has been used to produce recombinant human
thrombin [12]. However, to our knowledge, very little work
has been presented on the characterization of recombinant
ecarin (r-ecarin), and, nothing has previously been
published on how different prothrombin fragments and
prothrombin itself compare as substrates for r-ecarin,
compared to venom-prepared native ecarin. Here we show
that r-ecarin should be a better alternative for diagnostic
use than the currently used venom prepared enzyme.
2 Materials and Methods
2.1 Materials
2.1.1 Proteins
Puriﬁed human prothrombin was from JenAfﬁn GmbH
(Jena, Germany) or, from Enzyme Research Laboratories
(South Bend, IN, USA) and human prethrombin-2 protein
was obtained from Abcam PLC (Cambridge, UK), Prod.
No. ab62535. The proteins were stored at -20 C and
rapidly thawed at 37 C. Protein solutions containing dif-
ferent concentrations were prepared by dilution in Tris
buffer consisting of 0.05 M Tris HCl, 0.1 M NaCl, pH 8 at
37 C. The protein concentration after buffer exchange and
dilution of stock solutions was determined from the
absorbance spectrum between 250 and 350 nm, according
to the E280 provided by the supplier. Native ecarin, pre-
pared from the venom of E. carinatus, was from DSM
Nutritional Products Ltd. Branch Pentapharm (Basel,
Switzerland) and from Sigma Aldrich (St Louis, USA).
Ecarin was dissolved in 0.154 M NaCl to 10 EU/ml and
stored in aliquots at -20 C. Recombinant ecarin was the
crude cell culture supernatants from the cell line 11B9b.
Fresh ecarin solutions were prepared on the day of the
experiments (0.1 EU ecarin/ml).
2.1.2 Chemicals
The chromogenic thrombin substrate H-CHG-Ala-Arg-
pNa, was from JenAfﬁn GmbH and stored in Tris buffer at
?2t o?8 C. The second chromogenic thrombin substrate
S-2238 (H-D-Phe-Pip-Arg-pNa
.2HCl) was purchased from
Aniara Corp. (Ohio, USA). All chemicals were reagent
grade.
2.2 Methods
2.2.1 Thrombin Activity Measurements
By hydrolysis of the chromogenic thrombin substrates
H-CHG-Ala-Arg-pNa and S-2238 free pNA (paranitroani-
line) is generated that is monitored by the change in
absorbance at 405 nm (A405) in time (t) by spectropho-
tometry under conditions that the rate, dA405/dt, is linear
in the concentration of thrombin.
2.2.2 Production of r-Ecarin in CHO Cells
An ecarin encoding sequence optimized for expression in
mammalian cells was synthesized and cloned into the
Invitrogen vector pCDNA 3.1?. The complete expression
vector sequence is available under data base accession
FW582517.1. The translated amino acid sequence from the
optimized nucleotide sequence was the same as the one
reported by Nishida et al. [6]. This construct was used to
stably transfect CHO-S cells, obtained from Invitrogen,
according to procedures recommended by the cloning
vector supplier (Invitrogen, Life Technologies, UK). The
culture medium was CD-CHO from Invitrogen, and was
supplemented with Glutamax, HT-supplement and non-
essential amino acids as recommended by Invitrogen. The
cells were grown at 37 C in an atmosphere containing 5 %
carbon dioxide.
Clones were generated by limiting dilution cloning. To
screen for r-ecarin producing clones small samples from the
culture supernatant were removed and mixed with 10 mg/l
prothrombin to a ﬁnal concentration of 1 mg/l prothrombin
in assay buffer (50 mM Tris–HCl, pH 7.4 containing 0.1 %
BSA) and incubated 20–40 min at 37 C. The generated
thrombin was then detected by addition of an equal volume
of 1–2 mM solution of S-2238 in a 96 well Nunc F plate at
room temperature. The increase in absorbance at 405 nm
was monitored and the reaction was stopped when suitable
by addition of acetic acid (5 % ﬁnal concentration). To
produce r-ecarin for characterization, clone 11B9b was
grown in culture medium in shake ﬂasks until the cells were
no longer viable (approximately 7 days). After cell death,
incubation at 37 C was continued for at least 7 more days.
The ﬁnal activity of the produced r-ecarin was quantiﬁed in
the assay buffer at pH 7.4 and at 37 C against a standard of
venom derived ecarin from Sigma. The activity of r-ecarin
was compared with the JenAfﬁn internal native ecarin
standard in Tris buffer at pH 8.
2.2.3 Western Blot Detection of Ecarin
Strep-tagged mature ecarin (aa 191-616) was produced in
Escherichia coli by cloning the mature ecarin sequence
354 A. Jonebring et al.
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ecarin essentially as described by the vector supplier (IBA
GmbH, Germany). The puriﬁed r-ecarin was used for
raising polyclonal antisera in rabbits. For western blots cell
culture samples were reduced and run on 4–12 % SDS-
PAGE gradient gels and blotted onto nitrocellulose mem-
branes. Membranes were blocked with 5 % BSA in PBS
buffer and labelled with rabbit anti-ecarin serum and an
anti-rabbit immunoglobulin ALP-conjugate (Sigma cat. no.
A2306). Staining was done with BCIP/NBT (Sigma cat.
no. B5655).
2.2.4 Ecarin Activity Determination
For the determination of the ecarin activity the activation
of human prothrombin was evaluated in a simpliﬁed
spectrophotometric assay, using a chromogenic thrombin
substrate at 37 C. Since the generated activation products
from prothrombin, meizothrombin and thrombin, can
cleave H-CHG-Ala-Arg-pNa with similar activity [4] the
ecarin activity is measured from the change in A405 in time.
For estimation of the ecarin units and for the comparison of
the properties of r-ecarin and native ecarin the activity was
determined by measuring the rate from the time until a
threshold of absorbance, A405 = 0.1, was reached.
2.2.5 Ecarin Enzyme Kinetics
The characterisation and comparison of the activation of
human prothrombin and human prethrombin-2 by the two
ecarin preparations was made with a chromogenic assay at
pH 8. Prothrombin and prethrombin-2, respectively, were
cleaved by ecarin and the subsequent cleavage of the chro-
mogenic thrombin substrate, H-CHG-Ala-Arg-pNa, by the
activation products meizothrombin and thrombin, respec-
tively, was followed by the change in A405 in time. The
ecarin activity was calculated from the slope of the ﬁrst
derivative, dA405/dt versus time. The whole time curve was
recorded at 0.1 s intervals, allowing calculation of the ﬁrst
derivative of the whole progress curve to estimate the con-
version rate, id est the reaction rate of ecarin. For derivation
the Savisky-Golay smoothing factor was used with 4th
polynomial order and a window width of 9 data points.
The measurements were performed on Coatron M2
analyser (TECO Medical Instruments GmbH, Neufahrn,
Germany). First 125 ll of the solution with different con-
centrations of prothrombin or prethrombin-2 was added to
the microplate at room temperature, then 25 ll6 m M
H-CHG-Ala-Arg-pNa at 37 C, and, after 1 min incubation
in the analyser at 37 C, 50 ll ecarin solution (0.1 EU/ml,
to ﬁnal 0.025 EU/ml). The reaction curves were recorded
using Software TECMONI (TECO Medical Instruments
GmbH). The raw data were exported and stored in an Excel
ﬁle (Microsoft
) and transferred to GraFit version 5.0.13
(Erithacus, Software Limited) for determination of the ﬁrst
derivative and calculation of the rate. To ensure that the
concentration of the chromogenic substrate was in excess
during the whole reaction so that the rate of the chromo-
genic reaction depends on the prothrombin concentration
alone, only A405 values below 0.3 were evaluated.
3 Results and Discussion
3.1 Activation of r-Ecarin
Ecarin is expressed as a pro-protein and removal of the pro-
peptide is necessary for optimal ecarin activity. We found
that removal of the pro-peptide was obtained by continued
incubation of the cell culture for at least 7 days after the
death of the ecarin-producing cells. After the death of the
ecarin-producing cells the r-ecarin activity (Fig. 1) and the
amount of mature r-ecarin increased (Fig. 2).
The activity of the r-ecarin in the culture supernatant
from the clone 11B9b used for this work was calculated to
be 3.1 EU/ml, both with the activity assay with H-CHG-
Ala-Arg-pNa at pH 8 and the JenAfﬁn ecarin standard and
with the Sigma standard and the chromogenic thrombin
substrate S-2238 at pH 7.4.
3.2 Conversion of Prothrombin to Thrombin
by r-Ecarin
To estimate the amount of ecarin-containing culture needed
for converting prothrombin into thrombin, test digestions
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Fig. 1 Activation of r-ecarin in cell culture. Cell culture samples
were assayed for activity during the incubation time, as described in
Methods with 1 mM S-2238 and 1 mg/L (14 nM) prothrombin, using
native ecarin from Sigma as standard. Cell density million cells/ml
(diamonds); Active Ecarin EU/ml (squares)
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123were performed. Diluted ecarin-containing culture super-
natant samples were mixed with 1 g/l prothrombin in PBS
buffer and incubated at 37 C for 1–3 h. The digested
samples were then analysed by SDS-PAGE and the amount
of r-ecarin needed for complete conversion of prothrombin
into thrombin was estimated. With this information avail-
able we calculated that one litre of ecarin-containing cul-
ture supernatant containing 7000 EU could convert 64 g of
prothrombin into thrombin in less than 3 h at 37 C.
3.3 Enzyme Kinetic Properties of Native and r-Ecarin
For both native and r-ecarin, the reaction rate of pro-
thrombin cleavage was dependent on the prothrombin
concentration and increased rapidly in the concentration
range between 87 and 694 nM prothrombin although it did
not approach a maximal rate at the highest prothrombin
concentration, 868 mM, used (Fig. 3).
In Fig. 4 the curves for the conversion of prethrombin-2
both by r-ecarin and by native ecarin are shown. The ecarin
cleavage of prethrombin-2 was much slower than found for
prothrombin (Fig. 3). In contrast to for prothrombin, the
reaction curves for the cleavage of prethrombin-2 by native
ecarin and the following cleavage of the chromogenic sub-
strate are not comparable to the reaction curves of pre-
thrombin-2 cleavage by r-ecarin. Only for r-ecarin, the
reaction rate of prethrombin-2 cleavage increased in a con-
centrationrange between 87and347 nMprethrombin-2 and
approached a maximal rate at the highest prethrombin-2
concentrations. With native ecarin the reaction rate of pre-
thrombin-2 cleavage slowly increased over the whole con-
centration range tested, without reaching a plateau.
For the more accurate comparison of the reaction rates,
the curves as shown in Fig. 3 and 4 were evaluated by the
determination of the ﬁrst derivative, dA/dt, see example for
r-ecarin with prothrombin in Fig. 5. By linear regression the
slopes for each prothrombin concentration were then cal-
culated, representing the ecarin rate, and plotted versus the
concentration of prothrombin and prethrombin-2, respec-
tively, see Fig. 6. The kinetic constants were estimated by
non-linear curve ﬁtting to the simple Michaelis–Menten
equation. The only complete set of data points, allowing a
reliable estimate of the kinetic constants were thus obtained
with prethrombin-2 and r-ecarin, with a deﬁned Km of
0.4 lM. For the three other curves the Km values were less
well deﬁned, because of restrictions of the data sampling.
For prothrombin the Km value were roughly estimated to be
about 0.9 lM and 0.4 lM with recombinant respectively
native ecarin. The cleavage of prothrombin both by recom-
binant and native ecarin was comparable at prothrombin
concentrations below 250 nM, see Fig. 6. However, at
higher prothrombin concentrations far higher activity was
found with r-ecarin than with native ecarin since the rate of
hydrolysis with r-ecarin continued to increase, although
apparently with native ecarin it levelled off.
Non-activated
Mature 
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Fig. 2 Western blot analyses of r-ecarin in cell culture samples.
Numbers in the Figure denote day of sample collection from the cell
culture, and M denotes molecular weight marker (See Blue ?2 from
Invitrogen) (Color ﬁgure online)
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Fig. 3 Cleavage of human prothrombin by ecarin. Ecarin (ﬁnal 0.025
EU/ml) was added to prothrombin at different concentrations (ﬁnal
nM conc. as indicated) in Tris buffer at pH 8 at 37 C with 0.75 mM
H-CHG-Ala-Arg-pNa, monitored at 405 nm: A405 is plotted versus
time for the different prothrombin concentrations. Upper plot native
ecarin, lower plot r-ecarin
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1233.4 Discussion
We have successfully produced recombinant ecarin with
high yield in CHO cells and with an activity comparable to
the ecarin isolated from snake venom.
Although we successfully expressed mature ecarin in
E. coli, this protein was obtained as inclusion bodies
despite the presence of a secretory leader sequence and
successful processing of this leader sequence (results not
shown). The unusual amino acid composition of the mature
ecarin containing 35 cysteine residues may be an expla-
nation for the poor solubility and potentially also to the
extreme stability of r-ecarin in the presence of dead CHO
cells; the r-ecarin was found to be stable for months at
room temperature with debris of the host cells present
(results not shown). The larger molecular weight of the
mature ecarin produced in CHO (*70 kDa) compared to
the E. coli produced ecarin (*50 kDa), suggests that the
CHO-produced ecarin is glycosylated (data not shown).
Nishida et al. [6] predicted that there are 4–5 glycosylation
sites in the mature ecarin. Glycosylation may be important
to the solubility of ecarin, further explaining the inclusion
bodies obtained in E. coli.
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Fig. 4 Cleavage of human prethrombin-2 by ecarin. Ecarin (ﬁnal
0.025 EU/ml) was added to prethrombin-2 at different concentrations
(ﬁnal nM conc. as indicated) in Tris buffer at pH 8 at 37 C with
0.75 mM H-CHG-Ala-Arg-pNa, monitored at 405 nm: A405 is plotted
versus time for the different prethrombin-2 concentrations. Upper plot
native ecarin, lower plot r-ecarin
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Fig. 5 Activation of prothrombin by r-ecarin from thrombin activity.
The recarin curves in Fig. 3 were analysed by calculation of the ﬁrst
derivative; dA405/dt plotted versus time (ﬁrst derivative using 9 data
points window width and 4th polynomial order) with ﬁnal nM conc.
prothrombin as indicated
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Fig. 6 Estimation of Km and Vmax for pre- and prothrombin with
ecarin. The slopes of the curves as exempliﬁed in Fig. 5 are plotted
versus the protein concentration to obtain the data for prothrombin
(closed symbols) with r-ecarin (circles) or native ecarin (triangles).
Similarly, the data for the other curves were deduced from Fig. 3 and
4, but with open symbols for prethrombin-2 as the protein substrate.
The lines were drawn by non-linear regression applying the Michae-
lis–Menten equation
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noted that the mature ecarin is prone to aggregation already
at low concentrations. In snake venom native ecarin may
interact with other proteins that prevent aggregation and
reduce stability; solutions containing native ecarin are not
stable at room temperature. Western blot analyses of
r-ecarin in culture samples suggest that aggregates accu-
mulate simultaneously with the processing to mature ecarin
(Fig. 2).
The activity of r-ecarin and native ecarin was compa-
rable at prothrombin concentrations up to 250 nM. At
higher prothrombin concentrations the activity for r-ecarin
was higher than for native ecarin with an approximate
double turnover. This ﬁnding is consistent with the rapid
conversion by r-ecarin of prothrombin into thrombin. The
apparent different afﬁnities of native and r-ecarin for pre-
thrombin-2 suggest that different proteases could be pres-
ent in the native ecarin preparation, since the kinetics with
r-ecarin was better deﬁned. The reason for the difference
between native and r-ecarin in turnover at high prothrom-
bin concentrations is not understood, but it can be specu-
lated that proteins interacting with native ecarin in snake
venom affect the catalytic properties. Native ecarin prep-
arations available to us were not sufﬁciently pure to
exclude this possibility.
Ecarin puriﬁed from snake venom is currently used as
prothrombin activator in diagnostic reagents for measure-
ment of total prothrombin in plasma or for quantitative
determination of direct thrombin inhibitors [7]. The use of
components puriﬁed from snake venoms for such purposes
has many drawbacks. Many of the snake species are
endangered and the snakes have to be bred in special
facilities. Handling of snakes and the venom is potentially
dangerous as in addition to the prothrombin activators
many other toxic components are present. Furthermore,
differences among snake populations and in puriﬁcation
procedures create batch to batch variability. Development
of recombinant ecarin will offer a more standardised acti-
vator of prothrombin.
In conclusion, r-ecarin was identiﬁed as a promising
candidate for replacement of native ecarin in assays uti-
lizing conversion of prothrombin to thrombin.
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